Earnings ·
Treace Medical Concepts reported second quarter 2026 financial results on August 7, 2026
TMCITreace Medical Concepts, Inc.
Treace Medical Concepts reported second quarter 2026 financial results on August 7, 2026. Revenue decreased 4% to $45.4 million from $47.4 million in the prior year period. The company posted a net loss of $(15.9) million, or $(0.24) per share, compared to a $(17.4) million loss in the same quarter last year. Adjusted EBITDA was $(3.5) million, slightly improved from $(3.6) million previously. Year-to-date cash usage decreased by 57% ($3.6 million), with total liquidity of $45.6 million as of June 30, 2026. Management raised full-year 2026 revenue guidance to a range of $204 million to $212 million and updated the expected Adjusted EBITDA loss range to $(3.0) million–$(5.0) million. The company operates in the medical technology industry, specializing in surgical treatments for bunions and foot deformities.